IP Library Patent Application 16964846
Patent Application
App. No. 16/964,846

CANNABINOID DOSING REGIME FOR ACNE

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/964,846
Abstract

A treatment regime for use in the treatment or prevention of acne, said regime comprising the administration of: a) between 50 mg and 3000 mg of a topical liquid or gel composition comprising between 1% w/w and 15% w/w cannabinoid, wherein the cannabinoid is dissolved in the liquid or gel composition.

Claims (20)

1 . A treatment regime for use in the treatment or prevention of acne, said regime comprising the administration of:

a) between 50 mg and 3000 mg of a topical liquid or gel composition comprising between 1% w/w and 15% w/w cannabinoid, wherein the cannabinoid is dissolved in the liquid or gel composition.

2 . The treatment regime of claim 1 , wherein the topical composition is administered to the skin between 1 and 5 times per day.

3 . The treatment regime of claim 1 , wherein the topical composition delivers between 20 mg and 400 mg of cannabinoid per administration.

4 . The treatment regime of claim 1 , wherein the total daily dose applied to the skin is between 20 mg and 2000 mg cannabinoid.

5 . The treatment regime of claim 1 wherein:

a) the topical composition comprises 2.5% w/w or 5% w/w cannabinoid; and/or

b) the regime delivers 37.5 mg, 75 mg or 150 mg of cannabinoid per day.

6 . The treatment regime of claim 1 , wherein the cannabinoid is delivered in a composition comprising: (i) a volatile solvent; and (ii) a residual solvent that is less volatile than (i).

7 . The treatment regime of claim 6 , wherein the volatile solvent is a non-polymeric siloxane.

8 . The treatment regime of claim 6 , wherein the volatile solvent is a combination of a non-polymeric siloxane and a C2-C6 alcohol.

9 . The treatment regime of claim 8 , wherein the composition comprises 85-95% w/w siloxane and 1-10% wt/wt C2-C6 alcohol.

10 . The treatment regime of claim 9 , wherein the siloxane has two or three silicon atoms per molecule.

11 . The treatment regime of claim 10 wherein the siloxane is hexamethyldisiloxane.

12 . The treatment regime of claim 6 , wherein the residual solvent is a compound from the list comprising: fatty acids, fatty acid alcohols, fatty alcohols, glycols, alkanes, ethers of any of these, and combinations thereof.

13 . The treatment regime of claim 12 , wherein the composition comprises 1-10% wt/wt of residual solvent.

14 . The treatment regime of claim 13 , wherein the residual solvent is a compound from the list comprising: alkyl polypropylene glycol, polyethylene glycol ether, oleyl alcohol, isostearyl alcohol, octyldodecyl alcohol, 2-hexyl decyl alcohol, isohexadecane.

15 . A method for treating or preventing acne, said method comprising the administration of:

a) between 50 mg and 3000 mg of a topical liquid or gel composition comprising between 1% w/w and 15% w/w cannabinoid.

16 .- 32 . (canceled)

Assignments (2)
SECURITY INTEREST Recorded Jun 9, 2025
From: BOTANIX PHARMACEUTICALS LTD; BOTANIX SB INC.
To: KREOS CAPITAL VII (UK) LIMITED
Reel/Frame 071363/0010 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 17, 2023
From: CALLAHAN, MATTHEW
To: BOTANIX PHARMACEUTICALS LTD.
Reel/Frame 063981/0308 →